✨ Your Portfolio is fetched and updated from zerodha.

Zydus Lifesciences Ltd.

ZYDUSLIFE

Market Cap
₹1,00,810 Cr.
P/E
24.05

Zydus Lifesciences Ltd.

  • Zydus Lifesciences
  • Torrent Pharma
  • Alkem Laboratories
  • TJI Pharma
FAQs on Zydus Lifesciences Ltd. Shareprice

Zydus Lifesciences has given better returns compared to its competitors.
Zydus Lifesciences has grown at ~72.72% over the last 1yrs while peers have grown at a median rate of 60.58%

Yes, Zydus Lifesciences is expensive.
Latest PE of Zydus Lifesciences is 24.06, while 3 year average PE is 22.71.
Also latest EV/EBITDA of Zydus Lifesciences is 17.17 while 3yr average is 15.72.

View FAQ's On Business
Growth Table
  • Zydus Lifesciences Ltd.
  • Torrent Pharma
  • Alkem Laboratories
Balance Sheet
  • Zydus Lifesciences Ltd.
  • Torrent Pharma
  • Alkem Laboratories
Balance Sheet Snapshot
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
*Data is as of latest FY end
Profit & Loss
  • Zydus Lifesciences Ltd.
  • Torrent Pharma
  • Alkem Laboratories
Cash Flow
  • Zydus Lifesciences Ltd.
  • Torrent Pharma
  • Alkem Laboratories
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
Ratios
= Dominant Factor
  • Zydus Lifesciences Ltd.
  • Torrent Pharma
  • Alkem Laboratories
Quarterly Results
  • Zydus Lifesciences Ltd.
  • Torrent Pharma
  • Alkem Laboratories
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Rhapson method.
Learn how to use Reverse DCF
FAQs on Zydus Lifesciences Ltd. Financials

Balance sheet of Zydus Lifesciences is strong.
It shouldn't have solvency or liquidity issues.

The debt of Zydus Lifesciences is decreasing.
Latest debt of Zydus Lifesciences is -₹1,441.1 Crs as of Mar-24.
This is less than Mar-23 when it was ₹17.8 Crs.

Yes, profit is increasing.
The profit of Zydus Lifesciences is ₹4,206 Crs for TTM, ₹3,860 Crs for Mar 2024 and ₹1,960 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Zydus Lifesciences latest dividend payout ratio is 7.82% and 3yr average dividend payout ratio is 14.83%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

View FAQ's On Shareholding
timeline Timeline
watchlist Watchlist
portfolio Portfolio
alerts Alerts
filter Research
filter Stock Screener
markets Market
raw materials Raw Material
Data feed provided by Accord Fintech